

## **Pfizer Launches PAP Connect—New Online Enrollment Platform Simplifies Process to Access Select Pfizer Medicines for Eligible Patients**

For more than 30 years, Pfizer has been helping eligible US patients in need get access to their Pfizer medicines through a range of assistance programs. Recently, Pfizer launched a new online enrollment platform to make it easier for patients and their health care providers to get access to *select* Pfizer medicines. The platform, known as Pfizer PAP Connect, could not have come at a better time, given the stay-at-home orders executed across the country due to COVID-19 that have constrained patients from seeing their health care providers. The online enrollment option can be used for many of the most commonly requested primary care medications available through the Pfizer Patient Assistance Program (PPAP), which provides certain free Pfizer medicines to eligible insured and uninsured patients through their doctor's office or at home.

"In order to better serve our patients, we are pleased to provide a platform that enables patients to apply to the program and check on application status as well as product delivery 24-7, all online," said Niesha Foster, Vice President, Product Access at Pfizer.

With the introduction of Pfizer PAP Connect, eligible new and reenrolling patients and their doctors can start and complete the enrollment process entirely online, without signing paper applications and making phone calls. For patients without access to computers, digital devices, or the internet, the paper process will also be maintained.

Once a patient and the health care provider have applied to the Pfizer Patient Assistance Program (PPAP) using PAP Connect, they can check on the patient's enrollment status. Once enrolled, they can also view and track medication shipments, request prescription refills, all in one place. Essentially, PAP Connect is a one-stop option that can be securely accessed anywhere from a computer, mobile phone, or tablet.

A 2009 survey of provider perspectives on patient assistance programs published in the *Journal of Oncology Practice* found that the application completion process for patient assistance programs took anywhere from 2-5 days, requiring professional staff time and an average of 36 hours for the patient or caregiver to return his or her portion of the application. Common delays in the approval process of up to an average of 8 days were caused by incomplete applications. We've come a long way since then, and now with the availability of PAP Connect, Pfizer hopes to overcome barriers to the enrollment process and provide easier and faster access to select Pfizer medicines for patients in need.

PAP Connect works in concert with Pfizer RxPathways. Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. RxPathways is one way Pfizer demonstrates its commitment to equity by providing access to our medicines to reduce health care disparities.

For more information and a complete list of medicines available for online enrollment, please visit:  
[www.PfizerRxPathways.com](http://www.PfizerRxPathways.com).